Extracellular Vesicles: Biovectors and Biomarkers {#S1}
=================================================

Extracellular vesiculation is an evolutionary conserved fundamental activity of both normal and diseased cells ([@B38]). As an integral part of cell growth, aging, or development ([@B45]), as a way to get rid of unneeded cellular material, or as a means of intercellular, interorgan, and interspecies crosstalk ([@B36]), extracellular vesiculation is a key homeostatic mechanism contributing to survival, function, remodeling, and repair processes ([@B11]). As cells transfer materials inside or outside them by secretory and transport vesicles, absolutely healthy, stressed, or activated cells release nanosized membrane-enclosed extracellular vesicles (EVs) to the external environment. Within blood circulation, EVs have a short half-life (from a couple of minutes to a few hours), before being taken up by neighboring or distant cells.

The highly dynamic and omnipresent EV compartment consists of a heterogeneous group of small exosomes (typically \<150 nm), medium sized microvesicles (MVs, or microparticles, typically \<1 μm), large sized apoptotic bodies, and several other EV subtypes ([@B57]). On a constitutive basis or in response to stimulation, a cell can produce a wide variety of EVs. Their phenotype, biophysical characteristics, and biogenesis may overlap so much between each other and with non-EV components (e.g., plasma protein aggregates) so EVs characterization or classification is often a brainteaser.

Release of membrane vesicles is not a stochastic process but rather a regulated, highly selective cellular ability. It may have negative effects when overactivated, for example, during inflammation. The EVs bear "real-time" molecular signatures of the physiological states of the parental cells and their microenvironment. Based on those compositional and functional correlations, EVs are considered noninvasive predictive, diagnostic, and biomonitoring factors for the development and propagation of several diseases, including cardiovascular events ([@B64]) and structural renal injury ([@B82]), among others.

Moreover, according to numerous *in vitro* and *in vivo* data, material delivered by plasma EVs to recipient cells may induce immunomodulation, inflammation, oxidative stress, thrombogenesis, and vascular senescence or dysfunction ([@B38]; [@B12]; [@B79]; [@B14]; [@B15]; [@B41]). This is quite reasonable for competent carriers endowed by nature with a remarkable efficiency to preserve their cargo intact and active along their journeys. Secreted cytokines, for example, are more stable inside EVs than free in plasma ([@B29]). *Vice versa*, the levels of circulating EVs are increased in diseases associated with inflammation or coagulation ([@B70]), while proinflammatory and procoagulant factors promote the extracellular vesiculation by healthy cells *in vitro*.

Cardiovascular abnormalities represent the leading cause of increased morbidity and mortality in patients with chronic kidney disease (CKD), which may result to end-stage kidney disease (ESKD) ([@B7]). The molecular mechanisms underlining CKD have been associated with a pathophysiological context of chronic inflammation, anemia, accumulation of uremic toxins, increased oxidative and metabolic stresses ([@B8]), deregulation of calcium and phosphate homeostasis, coagulation and vascular abnormalities, and chronic or acute \[e.g., by hemodialysis (HD)\] endothelial activation ([@B33]). Of note, all of these pathologies have also been related to EV biology, either as stress factors triggering EV release or as outcomes of EVs' effects on sensitive cell targets. Those bidirectional connections reflect the dual role of EVs as both biomarkers of cell dysfunction and vectors of bioactive molecules contributing to it ([Figure 1](#F1){ref-type="fig"}). Not surprisingly, CKD patients have elevated concentration of EVs in body fluids ([@B4]).

![The chronic kidney disease (CKD)-related pathophysiological factors, treatment modalities, and comorbidities affect the cellular stress and activation status of endothelium and blood cells, leading to augmented release of extracellular vesicles (EVs) in the plasma. EVs contain molecular components of parental cells, and thus, are considered biomarkers of disease phenotypes. EV release may represent a cytoprotective mechanism allowing, among other, removal of stress or death signals from donor cells. Interactions of plasma EVs with recipient cells and plasma components may be involved in the progress of the primary disease *per se* and its cardiovascular complications in both directions, either by transmitting and amplifying dangerous, cellular response modifiers or by counteracting them. The "Janus face" is a general feature of EVs functional potential, related to their complex biology, in both donor and recipient cells. Advances in EV research have provided sharper pictures of plasma EVs in CKD, identifying them as key parts of both problem and solution.](fcell-08-00227-g001){#F1}

EVs in the Plasma of CKD Patients: General Outline of Our Knowledge {#S2}
===================================================================

Endothelium and blood cells in CKD are characterized by increased rate of extracellular vesiculation. Significant proportion of EVs (in most studies, MVs) that are released following activation of the origin cells ([@B8]) expose phosphatidylserine (PS; [@B28]; [@B13]; [@B76]) and are prothrombotic, often more than the parent cells ([@B63]), according to both morphological and biochemical evidence ([@B31]; [@B76]). The intriguing finding that the platelet-derived MVs are less procoagulant than in other diseases ([@B68]) (probably due to functional defects in platelets) does not break up the intimate relation of EVs with thrombosis in CKD, as uremic patients with thrombotic events have more MVs compared to those without events ([@B6]). Moreover, PS on plasma EVs may nucleate calcium phosphate, contributing to ectopic calcification reactions ([@B74]). Therefore, pharmacological blocking of the PS binding sites on cells and EVs or lipid lowering drugs ([@B3]) have been considered as meaningful measures to prevent thrombosis and vascular calcification risk in CKD. Of note, CKD patients with vascular calcification have both more circulating endothelial MVs and less endothelial progenitor cells compared to patients without calcification. This looming imbalance in endothelial damage and repair processes is probably induced by the MV-mediated expression of osteocalcin ([@B65]).

Several cross-talking factors seem to augment extracellular vesiculation in CKD ([Figure 1](#F1){ref-type="fig"}). Uremic toxins constitute the central one. To support, the PS^+^ EV levels *in vivo* are inversely correlated with the glomerular filtration rate ([@B3]; [@B76]), but positively with uric acid and proteinuria levels ([@B76]). More procoagulant MVs are detected in diabetes mellitus patients with CKD compared to patients without it ([@B3]), and in patients with extreme albuminuria than in those with lower or normal levels ([@B76]). To get a laboratory verification, incubation of normal endothelial cells or red blood cells (RBCs) with (i) patients' serum, (ii) uremic toxins at concentrations found in patients, or (iii) increased concentration of phosphate induce PS exposure on cells and EVs release ([@B28]; [@B1]; [@B30], [@B31]; [@B76]).

Another informative (inverse) correlation of endothelial MVs with shear stress is repeatedly detected in ESRD patients. It suggests that variations in shear-stress determinants and blood viscosity, including anemia and hemoconcentration arisen by the dialysis or erythropoietin (EpO) supplementation, may affect the vesiculation rate in the endothelium ([@B10]). Indeed, more endothelial cell-derived MVs have been detected in child and adult dialysis patients with CKD, than in patients not getting dialysis ([@B24]; [@B52]), but those findings may merely reflect the clinical severity of the disease. When comparing patients of similar clinical severity, both inflammation and repetitive mechanical stress, imposed on endothelium and blood cells by hemodialysis, still seem to augment vesiculation ([@B20]). The same inducers modify the EV phenotypes and micro-RNA (miRNA) cargos, often in cell-specific ([@B28]; [@B68]), or dialysis modal-specific ways ([@B18]). For instance, MV concentration is lower in patients treated by hemodiafiltration versus conventional hemodialysis ([@B34]). By examining the short-term effects of a single dialysis session on EV measurements, dialysis still triggers release of MVs but again, with marked differences between high-flux and low-flux dialyzers ([@B21]). As to the accumulation of the PS-exposing MVs ([@B34]) and smaller EVs ([@B58]), dialysis generally exerts a beneficial acute effect, mediated in part by EV absorbance to the dialysis membrane ([@B58]), at least in patients with adequate response to EpO ([@B35]). Additionally, hemodialysis seems to be more effective in eliminating small compared to bigger EVs ([@B58]). There is evidence that EpO affects platelet activation and promotes EV accumulation ([@B6]). This is quite interesting, because endothelium damage and cardiovascular disease appear more frequently in EpO resistance ([@B56]). Despite that, several renal-protective EpO signaling pathways are proceeded through stimulating EV release by both mesenchymal stem cells ([@B72]) and bone marrow cells ([@B83]). Finally, patients on hemodialysis are regularly exposed to considerable amounts of phthalates leaching by plastic tubing ([@B27]). Although the field is aware of the associated risks, the probable contribution of phthalates on comorbidities ([@B48]) and extracellular vesiculation \[extensively studied in stored blood ([@B60])\], as well as their probable dissemination to sensitive targets through EVs, have not been investigated so far in CKD.

What is the Message of Circulating EVs in CKD? {#S3}
==============================================

Like other pathologies, EVs represent phenotypic markers of cellular stress and activation in CKD. More importantly, their number and composition may also play a role in the pathophysiology of cardiovascular complications, and thus in mortality risk ([@B16]).

On one side, a wide panel of "incriminating" bioreactive phenotypes have been detected in plasma EVs of ESRD patients. Apart from PS, those phenotypes include platelet activation markers, tissue factor (TF), IL-1β, miRNAs ([@B61]), and advanced glycation end products (AGEs) receptor ([@B66]), which are potentially involved in coagulation, inflammation, oxidative stress, and endothelial activation/dysfunction ([@B66]; [@B21]). Endothelial dysfunction, arterial stiffness, and atherosclerosis are determinants of cardiovascular risk in patients with or without CKD. Flow cytometry, functional measurements, and Kaplan--Meier survival analysis have showed that the concentration of endothelium-derived MVs in ESRD selectively correlates with arterial dysfunction *in vivo* ([@B4]; [@B24]), and further predicts cardiovascular mortality ([@B5]). MVs released by cells exposed to uremic substances promote functional loss in endothelial progenitor cells (marked by overexpression of NF-κB and p53 proteins) ([@B17]) and TGFβ-mediated proliferation of vascular smooth muscle cells ([@B59]), while isolated ESRD MVs can impair NO release and endothelium relaxation ([@B4]). Endothelial dysfunction may be further related to activation of the alternative complement pathway and of note, endothelium-derived MVs in CKD do contain factor D and can activate the alternative pathway *in vitro* ([@B43]).

Endothelial dysfunction and fibrosis may be promoted in CKD by EV-mediated miRNA transfer mechanisms ([@B75]). miRNA present in MVs induced by uremic toxins disturb signaling pathways involved in endothelial regeneration through oxidative stress and apoptosis ([@B17]). Indeed, a series of miRNAs that mostly target TGFβ signaling-related mRNAs in recipient cells have been found enriched or depleted in plasma and plasma-derived exosomes and MVs from patients with CKD ([@B53]). miR-92a, for instance, is involved in atherosclerosis and cardiovascular disease as an effective suppressor of key endothelial-protective mRNAs. High serum levels of miR-92a have been associated with decreased kidney function. Moreover, endothelial MVs of uremic patients are enriched in miR-92a and uremic plasma upregulates its expression in cultured endothelial cells ([@B61]). Another miRNA, the miR-223 (which is abundant in resting platelets and further upregulated following platelet activation by pro-inflammatory factors), is enriched in platelet MVs of patients with nephritis, or atherosclerosis. It was found that miR-223 can promote apoptosis induced by AGEs in endothelial cells *in vitro* via targeting the insulin-like growth factor 1 receptor ([@B55]). Of note, a higher expression of miR-223 was found in the endothelial-derived exosomes and MVs of ESRD patients treated by bicarbonate hemodialysis compared to those treated by online hemodiafiltration and healthy subjects in close relation to variation in systemic inflammation markers ([@B18]).

Apart from the EV-delivered miR223, exosomes and MVs of ESRD patients with low levels of the Gla-rich protein (an anti-inflammatory factor and inhibitor of calcification in the cardiovascular system) can induce calcification in target vascular smooth muscle cells, by promoting osteogenic differentiation and inflammation ([@B71]). There is evidence that monocyte and endothelial MVs induce podocyte phenotypic modifications *in vitro* \[release of proinflammatory cytokines and vascular endothelial growth factor (VEGF)\] typically associated with glomerular permeability and proteinuria ([@B26]). Moreover, plasma platelet MVs can cause glomerular endothelial injury in animal models of diabetic nephropathy through transferring of chemokine ligand 7 (CXCL7) and activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway in glomerular target cells ([@B80]). Finally, recent studies revealed that plasma EVs in ESRD also contain the Klotho protein ([@B21]), a transmembrane component of the distal convoluted tubule of the kidney. Klotho expression declines with reducing renal function, and its deficiency has been speculated to contribute to vascular calcification ([@B42]).

On the other side, EVs release is also an "alarm button" pressed by cells facing life-threatening provocations. In RBCs, for example, extracellular vesiculation increases by aging, oxidative stress, and cold storage-associated lesions ([@B49]). Proteomic analyses of those EVs have suggested activity toward disposal of abnormal, nonfunctional, or dangerous materials (e.g., complement) that could otherwise signal premature elimination of releasing cells ([@B73]; [@B69]). In a similar way, release of caspase 3-containing EVs by endothelial cells *in vitro* protects them from apoptosis and detachment ([@B2]), suggesting that a similar mechanism may contribute to endothelial cell survival in CKD ([Figure 1](#F1){ref-type="fig"}). Consequently, it is reasonable to assume that increased release of PS^+^ RBC-derived EVs in CKD may counterbalance erythrophagocytosis leading to anemia ([@B35]). Complete phenotyping of EVs under various clinical and treatment conditions would test the accuracy of this assumption.

In addition, certain EVs may well induce anti-inflammatory responses in recipient cells ([@B32]), although these responses may vary in pathological conditions including hyperglycemia ([@B44]). miR-222 ([@B44]) and Hsp27 ([@B62]) laden plasma EVs, for example, were found to reduce tumor necrosis factor-alpha-induced ICAM-1 expression (and monocyte adhesion) and stimulate the release of IL-10 and NF-kappa in endothelial and B cells, respectively, both *in vitro* and *in vivo.* Moreover, plasma MVs that are released by the dysfunctional endothelium of patients with unstable angina are enriched in the miR-19b and exert antithrombotic function by inhibiting TF expression in endothelial cells ([@B50]). Several other miRNAs that are potentially encapsulated in plasma EVs, such as the miR-23b ([@B81]), have been shown to alleviate fibrosis and albuminuria in diabetic nephropathy, and thus, their levels are pathologically low in the serum and kidney of the patients. It is worth studying the degree of encapsulation of those cytoprotective miRNAs into the plasma EVs. Recent reports in animal models of kidney disease showed that miRNA expression is lower in plasma-derived exosomes compared to the plasma and that the miRNA levels may widely vary in each disease context ([@B75]). To sum up, plasma EVs may counteract proinflammatory and procoagulant signals instead of transmitting and amplifying them ([Figure 1](#F1){ref-type="fig"}), and thus, part of them may protect the vascular and kidney functions in CKD.

How Can We Read the Full Message and Move Forward? {#S4}
==================================================

EVs represent an exciting chapter of contemporary biology and medicine. The disproportionally high ratio of reviews to research articles dealing with plasma EVs in CKD ([Figure 2A](#F2){ref-type="fig"}) reflects a major interest for understanding a subject that is, however, difficult to be studied. Generally, research on EVs is a challenge for the scientific community, mainly due to their size, heterogeneity, artificial generation during the preanalytical stages, and lack of standardized methods of working with them ([@B22]). Let alone studying them in CKD patients characterized by extreme variabilities in primary lesions, comorbidities, and treatments, which individually and in synergy affect both their release and composition ([@B16]).

![(**(A)** Percentage of research and review articles dealing with plasma EVs in CKD published in the last decade (*N* = 56). **(B)** The vast majority of research data on plasma EVs in CKD derived in the period from 2002 till today (*N* = 37) were based exclusively on flow cytometry (FC). Fewer studies combined FC with other methodologies (immunoblotting, nanoparticle tracking analysis, proteomics, Elisa, electron microscopy) or they did not use FC at all. References are shown in the [Supplementary Material](#DS1){ref-type="supplementary-material"}.](fcell-08-00227-g002){#F2}

Despite that, research on EVs is critical for CKD for many reasons. First of all, we are now aware that EVs are key figures in the frame of this disease. They have to be taken into consideration, for instance, when measuring plasma cytokine levels in patients, because EV-encapsulated cytokines may not be detected by standard cytokine assays ([@B29]). Second, EVs have been associated with most of the cardiovascular risk factors ([@B41]) and with poor clinical outcomes in CKD as in many other diseases. Third, regular recording of clinical/laboratory data of CKD patients drives physicians to make individual, intervening decisions on treatments per short intervals of time. Consequently, availability of sensitive tools to support biomonitoring of the disease progression and identification of patients at risk are highly desirable. Finally, similar to their release, EVs uptake is also a specific and regulated process. Since EVs can cross the glomerular basement membrane, the possibility of using them as therapeutic vehicles targeting the kidney cells *per se* ([@B54]) open new prospects for CKD management.

Plasma EVs may provide peripheral biomarkers easily available for clinical diagnosis. The first step toward that is discovery of a reliable marker (or panel of markers) being related to a particular disease state, complication, or pathological condition. The candidate biomarker should then be appropriately validated *in vivo*, in animal disease models at first, and then, in cohorts of patients by clinical studies. Last is bridging of those biomarkers' capabilities to clinical setting. Isolation of EVs, especially exosomes, is not a clinically friendly procedure; however, development of simple and quick innovative separation methods (like the microfluidic based techniques) provides candidates for potential use in the clinical setting.

Biomarker mining presupposes availability of reliable EV metrical, compositional, physicochemical, and uptake ([@B78]) data. First of all, analytical methods able to detect and characterize the entire vesicular population, including the smaller (\<200 nm) EVs, must be used. The majority of data reported on plasma EVs in CKD have been extracted by flow cytometry, the "gold standard" analytical method for EVs characterization ([Figure 2B](#F2){ref-type="fig"}). However, conventional cytometry cannot detect vesicles \< 300 nm, the area that harbors the majority of EVs in human blood ([@B77]; [@B9]). Apart from that, it is now well established that only few blood EVs expose PS, namely, the most commonly used tag for flow cytometry ([@B19]; [@B9]). Despite insights provided by immobilizing smaller EVs on bead surfaces, and advances in the detection limits of new nanoscale instruments (100--200 nm) ([@B23]; [@B37]), the fact is that the biology and functions of smaller plasma EVs are largely unknown in CKD ([@B46]), in opposite to those of urinary exosomes ([@B25]). Of note, however, comparative proteomic analysis of RBC membrane in ESRD patients with good or poor response to EpO administration suggested release of small and/or PS-negative EVs in responders that are undetectable by the conventional flow cytometry ([@B35]).

Assessment of vesiculation by the protein concentration of a vesicular pellet is not accurate because pellets contain both disease specific and unspecific protein profiles, and moreover, they are unavoidably contaminated by plasma components ([@B22]). To get insight into EVs size and concentration, sophisticated physical methods like nanoparticle tracking ([@B23]; [@B13]) and tunable resistive pulse sensing analyses, in combination with cryo-electron microscopy, are currently used in the EV research field ([@B41]). Compositional analyses are more appropriately performed by immunoblotting, the much informative omics techniques, and by microfluidic devices allowing capture of EVs on a chip's surface and then lysis and probing of lysate, for identification of both surface and lumen components ([@B40]). Thermophoretic enrichment and profiling has been successfully tested for cancer detection and classification as an alternative method to detect surface proteins of plasma EVs, following labeling with fluorescent aptamers ([@B51]). Under such integrative characterization of plasma EVs, lack of specific protein markers to distinguish between their subtypes becomes less important.

Compositional analyses of EVs are of critical importance to understand the hows and whys of their biogenesis, stimuli, targets, and effects. Global and targeted mass spectrometry-based proteomic analysis is best suitable to suggest biomarker candidates ([@B82]), the cellular destinations of EVs, and thus, the most suitable therapeutic targets in a given patient or disease context. However, analysis of one data type by itself is often limited to correlations resulting by reactive processes rather than by causative modifications. Integration of multiomics ([@B39]), electron microscopy and physical characterization data ([@B67]) would rather reveal hidden aspects of EV biology and functions, offering the opportunity to understand the flow of material and information in CKD.

In a similar way, simple enumeration of EVs is not enough to establish a pathophysiological mechanism. Instead of it, time, place, and means of interactions (ligand binding, membrane fusion, or uptake by endocytosis), as well as identification of the specific molecular content(s) that mainly account for any given biological effect on target cells, are most critically connected to their desirable or harmful bioreactivity. However, this is also the hardest part in EV assessment. Incorporation of the guidelines suggested by the International Society for Extracellular Vesicles ([@B67]) would greatly benefit the emerging contemporary area of research on CKD-related EVs.

Conclusion {#S5}
==========

Plasma EVs may have significant roles in CKD as disease biomarkers, risk factors for the development of complications, repair or protective factors diffusing harmful stress signals, and finally, therapeutic factors. They seem to be part of the problem and part of the solution. At times when advanced technologies for EVs assessment are still evolving, understanding of their biology, from biogenesis to ultimate effects on recipient cells, is of key importance to reveal their clinical relevance to CKD. Development of therapeutic interventions have already been oriented to both block their negative effects and take advantage of their beneficial properties. Regulation of EVs release or uptake by drugs, including statins, antioxidants, and actin depolymerizing agents, and removal from plasma by immunoadsorption have been reported ([@B47]). Those interventions may allow prognosis, better diagnosis, and individualized treatments for CKD patients.
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